With advancements in neoadjuvant chemotherapy, particularly for breast cancer subtypes such as triple-negative and human epidermal growth factor receptor 2 (HER2)-positive tumors, more than 60% of patients can now achieve a pathological complete response [3–6]. This evidence concerns the gene ERBB2 and breast carcinoma.